REG - Destiny Pharma PLC - Appointment of Nominated Adviser and Sole Broker

Destiny PharmaAnnouncement

22/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240122:nRSV3547Aa&default-theme=true

RNS Number : 3547A  Destiny Pharma PLC  22 January 2024

Destiny Pharma plc
("Destiny Pharma" or "the Company")

Appointment of Nominated Adviser and Sole Broker

 

Brighton, United Kingdom - 22 January 2024 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life threatening
infections, is pleased to announce the appointment of Shore Capital and
Corporate Limited as its Nominated Adviser and Shore Capital Stockbrokers
Limited as its Sole Broker with immediate effect.

- END -

 

For further information, please contact:

 

Destiny Pharma plc
Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0) 127 370 4440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

FTI Consulting (Financial PR)

Ben Atwell / Simon Conway / Michael Trace / Victoria Foster Mitchell

+44 (0) 203 727 1000

destinypharma@fticonsulting.com

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.

 

 

For further information on the company, please visit www.destinypharma.com
(http://www.destinypharma.com)

 

Existing Board - AIM Rule 17 Disclosures

 

The Group announces the following information is being disclosed pursuant to
Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:

 

Sir Nigel Rudd - Chairman

 

Sir Nigel Rudd is a director of Loch Lomond Members Golf Club Limited. He was
appointed on 29 November 2010; as such this was a current directorship at the
date of the Company's announcement entitled "Appointment of new Chairman"
dated 25 July 2023.

 

Christopher Tovey - Chief Executive Officer

 

Christopher Tovey was a former director of GW Pharma (Germany) GmbH and GW
Pharma (France) SARL within 5 years of the date of the Company's announcement
entitled "Board changes including appointment of new CEO" dated 19 July 2023.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPBLGDBCUBDGSC